semaglutide 2.5 mg Sematrinity 2mg Pre-filled Pen A new study conducted by

Patients have filed a range of lawsuits over safety concerns around Ozempic, Wegovy, Mounjaro, and other prominent GLP-1s

These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued

Importantly, the required dosage of glutathione remains consistent whether the goal is skin whitening or just the health benefits

Jhaveri AM, Torchilin VP

As this is a phase 2 trial, the full long-term safety profile of retatrutide has not yet been established

They may be able to switch the anticholinergic to an alternative with less drying effect, reducing the total dry mouth burden